Ebola virus disease (EVD) causes viral hemorrhagic fever. It is a life threatening disease, which is spread to humans from animals. Direct contact with body fluids of infected person is one of largest causes of spread of this infection. Symptoms of Ebola disease include high fever, vomiting, sore throat, diarrhea, headache and muscular pain, and in few cases, internal or external bleeding. Although, there is no cure for Ebola virus disease, symptomatic treatment such as maintaining electrolyte balance, imagining required oxygen level, and treating infectious condition might help in improving patient’s health. Most of vaccines to prevent Ebola virus disease are under different developmental stage.

Ebola Vaccine Market Taxonomy:

On the basis of virus strain, the global Ebola vaccine market is segmented into:
Recombinant vesicular stomatitis virus-Zaire Ebola virus
Chimpanzee Adeno virus type 3-Zaire Ebola virus
Adeno virus serotype 26- Zaire Ebola Virus

In January 2018, GeoVax Labs Inc., published results tested in non-hamate primates for its experimental vaccine, GEO-EM01 against EVD. It is based on company’s novel Modified Vaccinia Ankara Virus like Particle (VLP) platform, which produces non-infectious VLPs in body of vaccinated individual. These VLP’S mimics the natural infection, which triggers the body to produce immune response with both antibodies and T cells.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/1365

GAVI is an international organization (global Vaccine Alliance) paid US$ 5 million to Merck & Company in 2016 for procurement of the vaccine (V 920 vaccine). Key players in the global Ebola vaccine market are Merck and Company, Janssen Pharmaceutica NV, GlaxoSmithKline, and Novavax Inc.